Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

NCT05351736 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Lurasidone

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico